Pefloxacin

Subscribe to Selected New Research on Pefloxacin

415 relevant articles (88 outcomes, 63 trials/studies) found for this Bio-Agent

Description: A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.

Also Known As:

2589 R.B.; Abactal; Peflacine; Pefloxacin Mesylate; Pefloxacine; Silver Pefloxacin; Mesylate, Pefloxacin; Pefloxacin, Silver; R.B., 2589; 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

2-Ring Heterocyclic Compounds

Quinolines: 58

Quinolones: 969

Fluoroquinolones: 1268

Pefloxacin: 415

pefloxacin N-oxide: 1

1-ethyl-6-fluoro-3-formyl-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxoquinoline

oxoperfloxacin

Experts

1.	Postnikov, S S: 3 articles (01/2002 - 01/2000)
2.	Polikarpova, S V: 2 articles (01/2002 - 01/2000)
3.	Semykin, S Iu: 2 articles (01/2002 - 01/2000)
4.	Brouet, Jean-Claude: 1 article (08/2007)
5.	Asli, Bouchra: 1 article (08/2007)
6.	Uzunhan, Yurdagul: 1 article (08/2007)
7.	Bienvenu, Boris: 1 article (08/2007)
8.	Arnulf, Bertrand: 1 article (08/2007)
9.	Fermand, Jean-Paul: 1 article (08/2007)
10.	Cordoliani, Florence: 1 article (08/2007)

Related Diseases

1.	Infection 06/01/1988 - "A better understanding of the pharmacokinetics of pefloxacin in human bone is warranted by the efficacy of this drug in the treatment of bone and joint infections" 01/01/1994 - "Pefloxacin was seen to be effective in preventing the onset of post-surgical infections (97%), also maintaining the clinical parameters considered within normal limits" 08/01/1986 - "The adequate penetration of pefloxacin into uninfected aqueous humour and lens suggests that this antibiotic may be effective in the treatment of certain bacterial endophthalmic infections." 01/01/1999 - "CONCLUSIONS: Pefloxacin resulted to be useful in the treatment of acute and chronic bone and joint infections" 01/01/2002 - "Pefloxacin (Abaktal)--efficacy in treating severe infections, optimization of treatment based on pharmacokinetic and pharmacodynamic parameters]" Get all the results and reference details, order at left...
2.	Typhoid Fever (Typhoid) 01/01/1998 - "The results indicate that pefloxacin is highly effective in the treatment of mouse typhoid even when the therapy is instituted after the suppression of bacterial growth in the reticuloendothelial system (RES)" 03/01/1989 - "Pefloxacin is a safe and effective agent for therapy of typhoid fever." 10/01/1990 - "The results of this study indicate that a seven-day course of pefloxacin 400 mg twice daily provides a suitable alternative in the treatment of typhoid fever." 06/01/1988 - "In a prospective, randomized trial, 42 patients with bacteriologically documented typhoid fever received either 400 mg pefloxacin b.i.d" 01/01/2006 - "Effects of pefloxacin in multi drug resistant typhoid fever." Get all the results and reference details, order at left...
3.	Peritonitis 06/01/1989 - "Resistance emerging after pefloxacin therapy of experimental Enterobacter cloacae peritonitis." 04/01/1989 - "In patients with spontaneous peritonitis, ascitic fluid cultures were positive in 11 cases, and organisms were sensitive to pefloxacin in 9 out of 11 cases" 01/01/1991 - "We conclude that pefloxacin might be equally effective in the treatment of peritonitis of CAPD after oral or IV administration" 06/01/1992 - "We conclude that oral pefloxacin is convenient, safe and effective enough as a single first line antimicrobial treatment for CAPD peritonitis." 06/01/1992 - "28 episodes of CAPD peritonitis were treated with a stat dose of pefloxacin 800 mg. followed by 400 mg. 12 hourly for about 15-18 days" Get all the results and reference details, order at left...
4.	Endocarditis 06/01/1990 - "Successful treatment of Brucella melitensis endocarditis with pefloxacin." 02/01/1988 - "At therapy days 4 and 10, approximately 30% of vegetations sampled from pefloxacin recipients contained bacteria for which pefloxacin MICs were four- to eightfold higher than the MIC for the parental strain used to initially induce endocarditis (MIC, 0.19 microgram/ml)" 03/08/1986 - "The therapeutic effectiveness of pefloxacin was evaluated in 15 patients admitted to an intensive care unit and suffering from septicaemia or endocarditis" 07/01/1984 - "In an experimental model of Escherichia coli endocarditis, diffusion into heart valves and infected vegetations and bactericidal effect of pefloxacin were also studied" 03/08/1986 - "Treatment of septicemia and endocarditis with pefloxacine" Get all the results and reference details, order at left...
5.	Urinary Tract Infections (Urinary Tract Infection) 01/01/1992 - "It is concluded that pefloxacin is a safe and effective alternative for treatment of complicated urinary tract infection." 09/28/1996 - "METHODS: A multicentric, randomized open trial was conduced in 595 patients by general practitioners to determine acceptability, efficacy and tolerance of lomefloxacine 400 mg in a once a day dose given for three days compared with a once-a-day 800 mg dose of pefloxacin for the treatment of lower urinary tract infection in women" 01/28/1995 - "OBJECTIVES: The aim of this randomized double-blind trial was to compare two 400 mg pefloxacin regimens either once-a-week or once-a-month applied for 48 weeks for the prophylaxis of recurrent urinary tract infection in women" 08/01/1994 - "Pefloxacin single-dose in the treatment of acute uncomplicated lower urinary tract infections in women: a meta-analysis of seven clinical trials." 01/28/1995 - "CONCLUSIONS: Once-a-week treatment with 400 mg of pefloxacin can be considered as a new effective and well tolerated approach for the prophylaxis of recurrent urinary tract infection in women and does not entail excessive emergence of pefloxacin resistant bacteria, even after 48 weeks of treatment." Get all the results and reference details, order at left...
176 Diseases and 415 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Ciprofloxacin (Cipro)
2.	Ofloxacin (Levofloxacin)
3.	Norfloxacin
4.	Cefotaxime (Kendrick)
5.	Gentamicins (Gentamicin)
6.	Amikacin (A.M.K)
7.	Fleroxacin
8.	Ceftazidime (Fortum)
9.	Ceftriaxone (Ceftriaxon)
10.	Ampicillin (Omnipen)
171 Drugs and Important Bio-Agents and 247 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
3.	Aftercare (After-Treatment)
4.	Retreatment
5.	Intensive Care (Surgical Intensive Care)
18 Therapies and Procedures and 37 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>